Center for Immunology of Emerging Infectious Diseases

登革病毒(DENV)对人类的感染作为一种新的传染病，其重要性稳步上升 疾病，DENV疾病保护性疫苗的开发因缺乏疫苗而受阻 了解病毒特异性免疫反应及其在保护和疾病中的作用。至 解决这些与DENV感染和疾病相关的关键问题，我们建立了一个独特的合作 美国-巴西新发传染病免疫中心(CIEID)研究联盟，包括 来自匹兹堡大学、约翰·霍普金斯医学院和 巴西累西腓的病毒学和实验疗法。CIEID的重点是进行全面的 用中国独有的临床标本分析人类对DENV感染的免疫应答 巴西临床核心研究--抗原提呈细胞在DENV中的初始作用 免疫病理学(项目1)，以确定T淋巴细胞与树突状细胞之间的相互作用 免疫与疾病的进展(项目2)，以确定DENV如何抑制先天免疫反应 DENV感染(项目3)，并确定已建立的常见T淋巴细胞反应的特异性 与DENV感染有关。这些翻译免疫学研究得到了一项技术开发的补充 旨在确定DENV病可靠生物标记物的项目(项目5)，由试点项目核心招募 新的研究领域和专业知识，由病毒学核心提供病毒和分子试剂，由 行政核心，协调项目活动和与CCHI网络指导委员会的互动。 预计拟议研究的结果将对以下方面的作用产生重要的新见解 感染和疾病中的DENV特异性免疫，然后可以为治疗和疫苗策略提供信息 发展。此外，预计美巴CIEID将提供平台技术和 翻译免疫学方面的全面专业知识，可轻松应用于其他新出现的感染 疾病或生物防御病原体。

Dengue virus (DENV) infections of humans has steadily increased in importance as an emerging infectious disease, and the development of protective vaccines to DENV disease has been impeded by a lack of understanding of the specificity of virus-specific immune responses and their role in protection and disease. To address these critical issues related to DENV infection and disease, we have established a unique collaborative research consortium, US-Brazil Center for Immunology of Emerging Infectious Diseases (CIEID) that includes investigators from the University of Pittsburgh, Johns Hopkins School of Medicine, and the Laboratory of Virology and Experimental Therapy in Recife, Brazil. The focus of the CIEID is to conduct a comprehensive analysis of the immune responses to DENV infection of humans using the unique clinical samples obtained from the Clinical Core in Brazil to characterize the initial role of antigen presenting cells in DENV immunopathogenesis (Project 1), to define the interaction of T-lymphocyte with dendritic cells in the progression of immunity and disease (Project 2), to define how DENV suppresses innate immune responses to DENV infection (Project 3), and to define the specificity of common T-lymphocyte responses that are established to DENV infection. These translational immunology studies are complemented by a Technology Development Project designed to identify reliable biomarkers of DENV disease (Project 5), by a Pilot Projects Core to recruit new research areas and expertise, by a Virology Core to provide viral and molecular reagents, and by an Adminstrative Core to coordinate project activities and interactions with the CCHI Network Steering Committee. It is anticipated that the results of the proposed studies will produce important new insights into the role of DENV-specific immunity in infection and disease that can then inform strategies for treatment and vaccine development. In addition, it is expected that the US-Brazil CIEID will provide platform technologies and comprehensive expertise in translational immunology that can readily be applied to other emerging infections diseases or biodefense pathogens.